Relationship Between Fluoroquinolones and the Risk of Aortic Diseases: a Meta-analysis of Observational Studies

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2020 Feb 5

PMID 32013928

Citations 10

Authors

Xiao-Ce Dai

Xin-Xin Yang

Lan Ma

Guan-Min Tang

Yan-Yun Pan

Hui-Lin Hu

Affiliations

Soon will be listed here.

Abstract

Background: Our aim was to determine the relationship between the use of fluoroquinolones and the risk of aortic diseases.

Methods: PubMed, EMBASE and the Web of Science were searched from inception to July 6, 2019, to identify observational studies that evaluated the risk of aortic diseases associated in users of fluoroquinolones compared with nonusers or users of other antibiotics. The primary outcome was the first occurrence of aortic diseases. We used the GRADE approach to rate the strength of evidence. We used the inverse variance method random-effect model to estimate the odds ratios (ORs) with 95% CIs, and statistical heterogeneity was assessed by the I statistic.

Results: This meta-analysis enrolled 2,829,385 patients reported the relationship between fluoroquinolones and the risk of aortic diseases. Compared with nonusers or users of other antibiotics, users of fluoroquinolone had a significantly increased risk of aortic diseases (adjusted OR, 2.10; 95% CI, 1.65-2.68; P = .000, I = 16.4%). The quality of evidence was moderate, and the number needed to harm (NNH) for aortic diseases among patients was estimated to be 1301.

Conclusions: The fluoroquinolone use in patients significantly increases the risk of new-onset aortic diseases. Clinicians need to pay attention to these severe adverse events when considering fluoroquinolone use.

Citing Articles

Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study.

Janetzki J, Kim J, Minty E, Lee J, Morales D, Khera R EClinicalMedicine. 2025; 81:103096.

PMID: 39975698 PMC: 11836508. DOI: 10.1016/j.eclinm.2025.103096.

Effect of FluoRoquinolones on Aortic Growth, aortic stIffness and wave refLEctionS (FRAGILES study).

Gardikioti V, Georgakopoulos C, Solomou E, Lazarou E, Fasoulakis K, Terentes-Printzios D Life (Basel). 2024; 14(8).

PMID: 39202735 PMC: 11355559. DOI: 10.3390/life14080992.

Impact of the US Food and Drug Administration warning regarding increased risk of aortic aneurysms or aortic dissections on fluoroquinolone prescribing trends.

Rizk J, Slejko J, Heil E, Seo D, Qato D BMJ Open Qual. 2024; 13(3.

PMID: 39053916 PMC: 11733791. DOI: 10.1136/bmjoq-2024-002925.

Safety of fluoroquinolones.

Barberan J, de la Cuerda A, Tejeda Gonzalez M, Lopez Aparicio A, Monfort Vinuesa C, Ramos Sanchez A Rev Esp Quimioter. 2023; 37(2):127-133.

PMID: 38140798 PMC: 10945095. DOI: 10.37201/req/143.2023.

Neurodegeneration, Mitochondria, and Antibiotics.

Suarez-Rivero J, Lopez-Perez J, Muela-Zarzuela I, Pastor-Maldonado C, Cilleros-Holgado P, Gomez-Fernandez D Metabolites. 2023; 13(3).

PMID: 36984858 PMC: 10056573. DOI: 10.3390/metabo13030416.

References

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

Clouse W, Hallett Jr J, Schaff H, Spittell P, Rowland C, Ilstrup D . Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc. 2004; 79(2):176-80. DOI: 10.4065/79.2.176. View

Meng L, Huang J, Jia Y, Huang H, Qiu F, Sun S . Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. Int J Clin Pract. 2019; 73(5):e13331. DOI: 10.1111/ijcp.13331. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Sommet A, Benevent J, Rousseau V, Chebane L, Douros A, Montastruc J . What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®. J Gen Intern Med. 2018; 34(4):502-503. PMC: 6445900. DOI: 10.1007/s11606-018-4774-2. View

Michalak K, Sobolewska-Wlodarczyk A, Wlodarczyk M, Sobolewska J, Wozniak P, Sobolewski B . Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications. Oxid Med Cell Longev. 2017; 2017:8023935. PMC: 5632915. DOI: 10.1155/2017/8023935. View

Frankel W, Trautner B, Spiegelman A, Grigoryan L, LeMaire S . Patients at Risk for Aortic Rupture Often Exposed to Fluoroquinolones during Hospitalization. Antimicrob Agents Chemother. 2018; 63(2). PMC: 6355567. DOI: 10.1128/AAC.01712-18. View

Lee C, Lee M, Chen Y, Lee S, Chen Y, Chen S . Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. JAMA Intern Med. 2015; 175(11):1839-47. DOI: 10.1001/jamainternmed.2015.5389. View

Rawla P, El Helou M, Vellipuram A . Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis. Cardiovasc Hematol Agents Med Chem. 2019; 17(1):3-10. PMC: 6865049. DOI: 10.2174/1871525717666190402121958. View

10.

Lee C, Lee M, Hsieh R, Porta L, Lee W, Lee S . Oral Fluoroquinolone and the Risk of Aortic Dissection. J Am Coll Cardiol. 2018; 72(12):1369-1378. DOI: 10.1016/j.jacc.2018.06.067. View

11.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

12.

Menon A, Pettinari L, Martinelli C, Colombo G, Portinaro N, Dalle-Donne I . New insights in extracellular matrix remodeling and collagen turnover related pathways in cultured human tenocytes after ciprofloxacin administration. Muscles Ligaments Tendons J. 2013; 3(3):122-31. PMC: 3838320. View

13.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

14.

Pasternak B, Inghammar M, Svanstrom H . Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018; 360:k678. PMC: 5842359. DOI: 10.1136/bmj.k678. View

15.

Olsson C, Thelin S, Stahle E, Ekbom A, Granath F . Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation. 2006; 114(24):2611-8. DOI: 10.1161/CIRCULATIONAHA.106.630400. View

16.

Bonkat G, Pilatz A, Wagenlehner F . Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. Eur Urol. 2019; 76(3):273-275. DOI: 10.1016/j.eururo.2019.06.011. View

17.

Davies H, Crombie I, Tavakoli M . When can odds ratios mislead?. BMJ. 1998; 316(7136):989-91. PMC: 1112884. DOI: 10.1136/bmj.316.7136.989. View

18.

Laupacis A, Sackett D, Roberts R . An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988; 318(26):1728-33. DOI: 10.1056/NEJM198806303182605. View

19.

Daneman N, Lu H, Redelmeier D . Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015; 5(11):e010077. PMC: 4654346. DOI: 10.1136/bmjopen-2015-010077. View

20.

Yu X, Jiang D, Wang J, Wang R, Chen T, Wang K . Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis. Drug Saf. 2019; 42(9):1025-1033. DOI: 10.1007/s40264-019-00828-z. View